Roche entered into an acquisition agreement with Cardion for acquiring rights to Cardion’s interleukin-15 antagonist, CRB-15 for treating rheumatoid arthritis and transplant rejection, thus substantially expanding its product portfolio in the fields of autoimmune diseases and transplantation...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: PharmaDeals Ltd